495 related articles for article (PubMed ID: 30343896)
1. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor.
Hu H; Mu Q; Bao Z; Chen Y; Liu Y; Chen J; Wang K; Wang Z; Nam Y; Jiang B; Sa JK; Cho HJ; Her NG; Zhang C; Zhao Z; Zhang Y; Zeng F; Wu F; Kang X; Liu Y; Qian Z; Wang Z; Huang R; Wang Q; Zhang W; Qiu X; Li W; Nam DH; Fan X; Wang J; Jiang T
Cell; 2018 Nov; 175(6):1665-1678.e18. PubMed ID: 30343896
[TBL] [Abstract][Full Text] [Related]
2. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas.
Bao ZS; Chen HM; Yang MY; Zhang CB; Yu K; Ye WL; Hu BQ; Yan W; Zhang W; Akers J; Ramakrishnan V; Li J; Carter B; Liu YW; Hu HM; Wang Z; Li MY; Yao K; Qiu XG; Kang CS; You YP; Fan XL; Song WS; Li RQ; Su XD; Chen CC; Jiang T
Genome Res; 2014 Nov; 24(11):1765-73. PubMed ID: 25135958
[TBL] [Abstract][Full Text] [Related]
3. High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation.
Huang R; Liu Y; Wang K; Wang Z; Zhang C; Zhang W; Zhao Z; Li G; Huang L; Chang Y; Zeng F; Jiang T; Hu H
CNS Neurosci Ther; 2021 May; 27(5):617-628. PubMed ID: 33645009
[TBL] [Abstract][Full Text] [Related]
4. Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.
Frampton GM; Ali SM; Rosenzweig M; Chmielecki J; Lu X; Bauer TM; Akimov M; Bufill JA; Lee C; Jentz D; Hoover R; Ou SH; Salgia R; Brennan T; Chalmers ZR; Jaeger S; Huang A; Elvin JA; Erlich R; Fichtenholtz A; Gowen KA; Greenbowe J; Johnson A; Khaira D; McMahon C; Sanford EM; Roels S; White J; Greshock J; Schlegel R; Lipson D; Yelensky R; Morosini D; Ross JS; Collisson E; Peters M; Stephens PJ; Miller VA
Cancer Discov; 2015 Aug; 5(8):850-9. PubMed ID: 25971938
[TBL] [Abstract][Full Text] [Related]
5. Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping.
Ou SI; Young L; Schrock AB; Johnson A; Klempner SJ; Zhu VW; Miller VA; Ali SM
J Thorac Oncol; 2017 Jan; 12(1):137-140. PubMed ID: 27666659
[TBL] [Abstract][Full Text] [Related]
6. Recurrent MET fusion genes represent a drug target in pediatric glioblastoma.
International Cancer Genome Consortium PedBrain Tumor Project
Nat Med; 2016 Nov; 22(11):1314-1320. PubMed ID: 27748748
[TBL] [Abstract][Full Text] [Related]
7. Tumour exosomes from cells harbouring PTPRZ1-MET fusion contribute to a malignant phenotype and temozolomide chemoresistance in glioblastoma.
Zeng AL; Yan W; Liu YW; Wang Z; Hu Q; Nie E; Zhou X; Li R; Wang XF; Jiang T; You YP
Oncogene; 2017 Sep; 36(38):5369-5381. PubMed ID: 28504721
[TBL] [Abstract][Full Text] [Related]
8. Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring
Engstrom LD; Aranda R; Lee M; Tovar EA; Essenburg CJ; Madaj Z; Chiang H; Briere D; Hallin J; Lopez-Casas PP; Baños N; Menendez C; Hidalgo M; Tassell V; Chao R; Chudova DI; Lanman RB; Olson P; Bazhenova L; Patel SP; Graveel C; Nishino M; Shapiro GI; Peled N; Awad MM; Jänne PA; Christensen JG
Clin Cancer Res; 2017 Nov; 23(21):6661-6672. PubMed ID: 28765324
[No Abstract] [Full Text] [Related]
9. Novel MET/TIE2/VEGFR2 inhibitor altiratinib inhibits tumor growth and invasiveness in bevacizumab-resistant glioblastoma mouse models.
Piao Y; Park SY; Henry V; Smith BD; Tiao N; Flynn DL; de Groot JF
Neuro Oncol; 2016 Sep; 18(9):1230-41. PubMed ID: 26965451
[TBL] [Abstract][Full Text] [Related]
10. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
11. Aberrant
Al-Ghabkari A; Huang B; Park M
Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
[TBL] [Abstract][Full Text] [Related]
12. Whole-transcriptome sequencing profiling identifies functional and prognostic signatures in patients with PTPRZ1-MET fusion-negative secondary glioblastoma multiforme.
Chen BS; Wang KY; Yu SQ; Zhang CB; Li GZ; Wang ZL; Bao ZS
Oncol Lett; 2020 Nov; 20(5):187. PubMed ID: 32952656
[TBL] [Abstract][Full Text] [Related]
13. An orally bioavailable c-Met kinase inhibitor potently inhibits brain tumor malignancy and growth.
Guessous F; Zhang Y; diPierro C; Marcinkiewicz L; Sarkaria J; Schiff D; Buchanan S; Abounader R
Anticancer Agents Med Chem; 2010 Jan; 10(1):28-35. PubMed ID: 20015006
[TBL] [Abstract][Full Text] [Related]
14. MET Inhibition Elicits PGC1α-Dependent Metabolic Reprogramming in Glioblastoma.
Zhang Y; Nguyen TTT; Shang E; Mela A; Humala N; Mahajan A; Zhao J; Shu C; Torrini C; Sanchez-Quintero MJ; Kleiner G; Bianchetti E; Westhoff MA; Quinzii CM; Karpel-Massler G; Bruce JN; Canoll P; Siegelin MD
Cancer Res; 2020 Jan; 80(1):30-43. PubMed ID: 31694905
[TBL] [Abstract][Full Text] [Related]
15. Recurrent PTPRZ1-MET fusion and a high occurrence rate of MET exon 14 skipping in brain metastases.
Chai RC; Liu X; Pang B; Liu YQ; Li JJ; Li YF; Zhao Z; Du J; Bao ZS; Jiang T
Cancer Sci; 2022 Feb; 113(2):796-801. PubMed ID: 34812554
[TBL] [Abstract][Full Text] [Related]
16. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma.
Johnson J; Ascierto ML; Mittal S; Newsome D; Kang L; Briggs M; Tanner K; Marincola FM; Berens ME; Vande Woude GF; Xie Q
J Transl Med; 2015 Sep; 13():306. PubMed ID: 26381735
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of Combination Therapy with MET and VEGF Inhibitors for MET-overexpressing Glioblastoma.
Okuda T; Tasaki T; Nakata S; Yamashita K; Yoshioka H; Izumoto S; Kato A; Fujita M
Anticancer Res; 2017 Jul; 37(7):3871-3876. PubMed ID: 28668888
[TBL] [Abstract][Full Text] [Related]
18. Patterns of response to crizotinib in recurrent glioblastoma according to ALK and MET molecular profile in two patients.
Le Rhun E; Chamberlain MC; Zairi F; Delmaire C; Idbaih A; Renaud F; Maurage CA; Grégoire V
CNS Oncol; 2015; 4(6):381-6. PubMed ID: 26498130
[TBL] [Abstract][Full Text] [Related]
19. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
[TBL] [Abstract][Full Text] [Related]
20. Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity.
Viotti J; Duplan E; Caillava C; Condat J; Goiran T; Giordano C; Marie Y; Idbaih A; Delattre JY; Honnorat J; Checler F; Alves da Costa C
Oncogene; 2014 Apr; 33(14):1764-75. PubMed ID: 23644658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
